In short
OMTX705 is an innovative antibody-drug conjugate currently being investigated in clinical trials for patients with advanced solid tumors. This open-label, multicenter Phase 1 study examines OMTX705 both as a standalone treatment and in combination with pembrolizumab (Keytruda) for patients who have exhausted standard treatment options. The trial aims to establish safe dosing levels, evaluate side effects, and gather preliminary data on the drug's effectiveness against various advanced cancers. This article summarizes key information about this ongoing research to help patients understand this potential new treatment approach.
Key points
- OMTX705 is a novel antibody-drug conjugate targeting fibroblast activation protein currently being investigated in a Phase 1 clinical trial for patients with advanced solid tumors. The study examines OMTX705 both as a standalone treatment and in combination with the immunotherapy drug pembrolizumab (Keytruda). The trial follows a dose-escalation design to determine the optimal dosing level while monitoring safety, side effects, and preliminary effectiveness. Researchers are collecting extensive data on how the drug behaves in the body, immune responses, and cancer biomarkers. The study specifically targets patients with advanced cancers who have exhausted standard treatment options.
At a glance
- Trial Design
- Open-label, two-parallel arm, multicenter, Phase 1 dose-escalation study
- Study Population
- Patients with advanced or metastatic solid tumors with no available standard therapeutic options
- Treatment Arms
- 1. OMTX705 monotherapy; 2. OMTX705 + pembrolizumab (Keytruda) combination
- Dosing Schedule
- OMTX705 administered on Days 1 and 8 in 21-day cycles, starting at 1.0 mg/kg
- Study Structure
- Part 1: Dose escalation to determine maximum tolerated dose; Part 2: Up to 4 expansion cohorts (up to 15 patients each) to confirm safety and assess tumor activity
- Primary Outcome
- Safety evaluation through frequency and grade of treatment-emergent adverse events
- Secondary Outcomes
- - Preliminary signs of antitumor activity; - OMTX705 pharmacokinetics; - OMTX705 immunogenicity
- Other Assessments
- - Cancer serum biomarkers; - OMTX705 biomarkers; - Payload metabolites; - QTc prolongation; - Cancer-associated fibroblasts
- Follow-up
- - End of Treatment visit 30 days after last dose; - Progression-free survival follow-up every 12 weeks; - Survival follow-up every 3 months (Part 2 only)
- Expected Timeline
- Average of 24 months
What is OMTX705?
OMTX705 is an investigational medication currently being studied for the treatment of advanced solid tumors. It belongs to a class of drugs known as antibody-drug conjugates (ADCs), which are specialized treatments that combine a targeted antibody with a cancer-killing drug. Specifically, OMTX705 is an anti-fibroblast activation protein antibody-drug conjugate, meaning it targets a specific protein found in the environment surrounding tumors.
Currently, OMTX705 is being investigated in clinical trials and is not yet approved for general use. The research is exploring its potential both as a single treatment (monotherapy) and in combination with another cancer drug called pembrolizumab (brand name Keytruda).
How OMTX705 Works
OMTX705 works by targeting fibroblast activation protein (FAP), which is found in cancer-associated fibroblasts (CAFs). These are special cells that exist in the environment surrounding tumors and can help cancer grow and spread.
The medication has two main parts:
- An antibody that specifically recognizes and attaches to the fibroblast activation protein
- A drug payload (called TAM470) that can kill cancer cells
By targeting these special cells in the tumor environment rather than just the cancer cells themselves, OMTX705 represents a different approach to cancer treatment.
Current Research on OMTX705
OMTX705 is currently being studied in a Phase 1 clinical trial (identified as NCT05547321). This study is designed to evaluate the safety and effectiveness of OMTX705 in patients with advanced or metastatic cancer who have no available standard treatment options.
The study has two main parts:
- Part 1: A dose-escalation phase with two parallel groups - one receiving OMTX705 alone and another receiving OMTX705 combined with pembrolizumab. This phase helps researchers find the right dose by starting with a low dose (1.0 mg/kg) and gradually increasing it while monitoring for side effects.
- Part 2: An expansion phase with up to 4 groups of patients (up to 15 patients each) to further confirm the safety of the selected dose and gather initial information about how effective the treatment might be against tumors.
Treatment Approaches with OMTX705
In the clinical trial, OMTX705 is being tested in two different approaches:
- Monotherapy: OMTX705 is given by itself to see how effective it is on its own.
- Combination therapy: OMTX705 is given together with pembrolizumab (Keytruda). Pembrolizumab is an immunotherapy drug that helps the body's immune system recognize and attack cancer cells. Researchers believe the combination might work better than either drug alone.
In the study, OMTX705 is administered on Days 1 and 8 in cycles of 21 days (meaning a 3-week cycle where you receive the drug twice).
Safety Monitoring and Evaluations
The main goal of the current study is to evaluate the safety of OMTX705. Researchers are carefully tracking any treatment-emergent adverse events (TEAEs) - side effects that appear during the course of treatment.
Throughout the study, researchers are monitoring:
- Safety: Tracking all side effects and their severity
- Pharmacokinetics: How the drug moves through the body, including how quickly it's absorbed, distributed, and eliminated
- Immunogenicity: Whether the body develops antibodies against the drug (anti-drug antibodies or ADAs)
- QTc prolongation: Monitoring heart activity through electrocardiography (ECG) to ensure the drug doesn't affect heart rhythm
- Biomarkers: Measuring changes in various markers in the blood that might indicate how the drug is working
Potential Benefits of OMTX705
While it's too early to know for certain how effective OMTX705 will be, the study is designed to look for signs of anti-tumor activity. Researchers are measuring the objective response rate (ORR), which includes:
- Complete response (CR): When all detectable cancer disappears
- Partial response (PR): When tumors shrink by a significant amount
These responses are measured using a standardized approach called RECIST 1.1 (Response Evaluation Criteria in Solid Tumors), which helps doctors consistently measure changes in tumor size.
Who Might Benefit from OMTX705
The current study is focusing on patients with advanced solid tumors who have no available standard treatment options. This means the cancer is either:
- Advanced: Cancer that has grown significantly within the organ it started in
- Metastatic: Cancer that has spread from its original location to other parts of the body
If the clinical trials show promising results, future studies might focus on specific types of solid tumors where OMTX705 shows the most benefit. The current study allows for "enrichment" of expansion groups with particular types of cancer where activity has been observed during the dose-finding phase.
It's important to note that OMTX705 is still in the early phases of clinical testing, and more research is needed before we know its full potential benefits and limitations for cancer treatment.